$4.66
Value $235M
CUVL and NVDA stock compared: price, dividend, valuation and results, from SEC filings.
$4.66
Value $235M
$128.28
Value $3.12T
Clinuvel Pharmaceuticals (CUVL) has a market value of $235M and NVIDIA (NVDA) $3.12T. Over the last year, with dividends, CUVL moved -32.5% and NVDA -31.1%. The P/E is 10.1 for CUVL and 16.2 for NVDA. Dividend yield: CUVL 0.71%, NVDA 0.41%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CUVL$235M
NVDA$3.12T
NVDA is 13,265 times CUVL
Revenue, 12 months
CUVL$64M
NVDA$303B
NVDA is 4,711 times CUVL
Net income, 12 months
CUVL$23M
NVDA$193B
NVDA is 8,322 times CUVL
Operating margin
CUVL43.4%
NVDA65.2%
21.8 points apart
ROIC
CUVL11.7%
NVDA95.6%
83.9 points apart
P/E
CUVL10.1
NVDA16.2
NVDA is 1.6 times CUVL
Dividend yield
CUVL0.7%
NVDA0.4%
0.3 points apart
5-year return
CUVL-79.3%
NVDA+290.5%
369.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CUVL-79.3%
NVDA+290.5%
| Period | CUVLWith dividends | NVDAWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -32.5%Price -32.9% | -31.1%Price -31.2% |
| 3 years since November 20, 2023 | -54.9%-23.3% a yearPrice -55.3% | +155.2%+36.7% a yearPrice +154.4% |
| 5 years since November 19, 2021 | -79.3%-27.0% a yearPrice -79.6% | +290.5%+31.3% a yearPrice +288.8% |
| 10 years since November 21, 2016 | -20.9%-2.3% a yearPrice -22.3% | +5,533.0%+49.6% a yearPrice +5,428.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CUVLClinuvel PharmaceuticalsNVDANVIDIA
| Price | $4.66 | $128.28 |
|---|---|---|
| Market value | $235M | $3.12T |
| Enterprise value (EV) | $61M | $3.09T |
| P/E | 10.1 | 16.2 |
| P/E, 5-year median | 15.9 | 49.9 |
| P/B | 1.3 | 13.6 |
| EV/EBIT | 2.2 | 15.7 |
| Free cash flow yield | 5.0% | 4.1% |
| Revenue, 12 months | $64M | $303B |
|---|---|---|
| Net income, 12 months | $23M | $193B |
| Free cash flow, 12 months | $12M | $127B |
| Earnings per share, 12 months | $0.46 | $7.91 |
| Revenue growth, year on year | 5.2% | 65.5% |
| Revenue growth a year, past | +5.4%over 2 years | +66.9%over 5 years |
| EPS growth a year, past | +0.0%over 2 years | +95.2%over 5 years |
| Gross margin | 82.9% | 74.7% |
|---|---|---|
| Operating margin | 43.4% | 65.2% |
| Net margin | 36.0% | 63.7% |
| ROIC | 11.7% | 95.6% |
| ROE | 12.3% | 120.4% |
| Cash | $174M | $56.6B |
|---|---|---|
| Total debt | $1.3M | $38.9B |
| Net debt / EBITDA | -6.2 | -0.1 |
| Interest cover | – | 426.7× |
| Dividend yield | 0.7% | 0.4% |
|---|---|---|
| Dividend per share, 12 months | $0.03 | $0.52 |
| Dividend growth a year, past | – | +20.1%over 5 years |
| Buyback yield | – | 1.3% |
| Shareholder yield | 0.7% | 1.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, NVIDIA ($3.12T) is about 13,264.5 times Clinuvel Pharmaceuticals ($235M), at today's prices.
Since November 21, 2016, CUVL's price moved -22.3% and NVDA's +5,428.0%. With dividends: CUVL -20.9% (-2.3% a year), NVDA +5,533.0% (+49.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.71% for Clinuvel Pharmaceuticals and 0.41% for NVIDIA. Over the last twelve months they paid $0.03 and $0.52 per share.
At today's price, the P/E is 10.1 for CUVL and 16.2 for NVDA. The median of the last five years was 15.9 and 49.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 36.0% for Clinuvel Pharmaceuticals and 63.7% for NVIDIA, and the operating margin 43.4% and 65.2%. Revenue was $64M and $303B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.